In conclusion, we first established a prognostic model containing 14 AS events, and verified by experiments, found that HERC4 (exon 23) and EPHX2 (exon 7) can be used as potential therapeutic targets for TNBC, and then constructed the regulatory network of AS events and SFs, identified DDX39B as the key node of SF, siRNA verification found that DDX39B can be used as a potential target for breast cancer treatment, which provides new ideas for breast cancer treatment. This evidence concerns the gene DDX39B and breast carcinoma.